Funding round · Up to US$100M
Affordable cancer vaccines, made in India.
PranAmritam is building India's first integrated platform for non-mRNA therapeutic cancer vaccines, covering cancer research, vaccine design and GMP manufacturing in one facility.
- New cancer cases in India every year
- 1.4M+
- Non-mRNA vaccine platforms in one pipeline
- 5
- Standard cold chain — no ultra-cold storage
- 2–8 °C
- Gated plan from pilot cohort to Phase II readout
- 84 mo
The opportunity
A strategic gap in India's cancer care
India has strong vaccine manufacturing and growing cancer research, yet no single company discovers, designs and manufactures therapeutic cancer vaccines in the country. Most cancer care is imported, and it is expensive.
PranAmritam fills that gap. Its portfolio is deliberately non-mRNA: stable, affordable and suited to India's existing healthcare infrastructure.
Investment thesis
Why non-mRNA platforms win in India
Stability
Peptide, protein and dendritic-cell vaccines stay stable at 2–8 °C or room temperature, unlike mRNA at −70 °C. They fit India’s distribution network.
Proven precedent
Sipuleucel-T, a dendritic-cell vaccine, is US FDA-approved for prostate cancer. Several peptide and viral-vector candidates are in late-stage trials around the world.
Manufacturing fit
The platforms use India’s existing strengths in recombinant protein, cell culture and GMP fill-finish.
Cost per patient
Goods cost less per patient than mRNA-LNP, so pricing can be affordable at scale.
Regulatory clarity
The platforms are well characterised, with established quality standards and long-term safety data.
Clinical evidence
Neoantigen DC vaccines controlled disease in 15 of 17 patients as a monotherapy
Published data also show more than 60% 3-year survival and durable outcomes in pancreatic cancer, with very few side effects.
The integrated model
Research, design and manufacturing in one place
Division 01
Cancer Research
Tumour antigen and neoantigen discovery from patient tumour/normal sequencing data.
Division 02
Vaccine Design
Lead platform: personalised multi-epitope peptide vaccines with immune-stimulating adjuvants.
Division 03
GMP Manufacturing
Grade B/C/D cleanroom suites for peptide synthesis and recombinant protein processing.
Roadmap
A milestone-gated path to the clinic
Starting with triple-negative breast cancer, every phase ends with a defined milestone, and most with a go/no-go gate, before more capital is committed.
- Phase 0Months 0–4
Governance, regulatory & logistics
M0 · All approvals in place, logistics lane validated, sequencing agreement signed
- Phase 1Months 4–10
Pilot cohort & sequencing validation
M1 · At least 20 samples sequenced and QC-passed; data pipeline validated end to end
- Phase 2Months 10–18
Analytics, neoantigen selection & vaccine design
M2 · Vaccine platform locked; first-cohort vaccine designs frozen
- Phase 3Months 16–26
Preclinical development & CMC
M3 · GMP clinical batch released; preclinical package complete
- Phase 4Months 22–28
Regulatory submissions
M4 · Clinical trial authorisation obtained
- Phase 4AMonth 28 onwards
Compassionate / special access
Parallel track alongside clinical phases
- Phase 5Months 28–48
Phase I first-in-human study
M5 · Phase I readout; go/no-go decision for Phase II
- Phase 6Months 48–84
Phase II efficacy signal
M6 · Phase II interim analysis and commercialisation decision
From the founders
Why we are building PranAmritam
Watch a short message about our mission: to make therapeutic cancer immunotherapy accessible and affordable across India by building the full chain from tumour antigen research to GMP vaccine manufacture.
Raising up to US$100M
Help build affordable cancer immunotherapy in India
Qualified investors can request the investor deck, financial model and data-room access.